No Data
The new forces in medicine under the surge of AI: Decoding the intelligent secrets behind YSB (9885.HK) performance turnaround.
Nowadays, AI unquestionably stands at the forefront, becoming the absolute main line chased by capital. The "AI + Medical" integration is seen by the market as the most explosive strategic high ground due to its potential to reconstruct traditional diagnostic and treatment models. As the AI wave sweeps through the healthcare industry, YSB (9885.HK), China’s largest outpatient pharmaceutical digital comprehensive service platform, recently presented its performance report for 2024, providing vivid proof of this technological revolution. The Earnings Reports show that the company's annual revenue grew by 5.5% year-on-year to 17.904 billion yuan, with net income exceeding 30.01 million yuan, achieving a full positive turnaround for the first time, with adjusted net income reaching.
Buzhen Zhang YSB Inc.'s (HKG:9885) CEO Is the Most Bullish Insider, and Their Stock Value Gained 11%last Week
YSB (09885) announced its 2024 performance, with a profit attributable to the owners of the company amounting to 30.013 million yuan, turning from a loss to a profit year-on-year.
YSB (09885) announced its 2024 performance, with revenue of approximately 17.904 billion yuan, a year-on-year increase of 5.5%;...
Express News | YSB Inc - FY Revenue RMB17.90 Bln
Express News | YSB Inc - Final Dividend of RMB 0.075 per Share for Year
YSB: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024
